VIP
Vasoactive Intestinal Peptide • Also called Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide appears frequently in biohacking and chronic-inflammation circles, but its current FDA signal is still an evaluation track rather than a settled compounding green light.
Current status
Pending Reclassification
Inflammation- and respiratory-related interest, with current federal compounding constraints still in play.
FDA category
Category 1
Can pharmacies compound this?
No
Reclassification expected?
Yes
FDA currently places VIP in Category 1, which is a stronger signal than Category 2 or 3, but it still falls short of a clearly established routine compounding pathway.
Primary Use
Inflammation- and respiratory-related interest
Also searched as
Vasoactive Intestinal Peptide
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 27, 2024
Current status signal recorded: Listed by FDA in Category 1 for ongoing evaluation under the 503A bulks process..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when VIP status changes
State-specific notes
California
Even with a better federal posture, specialty sterile peptides still face conservative sourcing.
Florida
Demand can be high, but pharmacy willingness still varies.